CAC Score (Coronary Calcium) Longevity-Medicine Target Ranges

What a CAC Score Actually Measures

A coronary artery calcium score quantifies calcified atherosclerotic plaque in the coronary arteries using non-contrast cardiac CT. The Agatston method, still the clinical standard, multiplies each lesion's area by a density coefficient and sums the result across all four major coronary territories. The output is a dimensionless number, though it behaves clinically like a continuous biomarker of cumulative plaque burden.

Calcium deposits form when atherosclerotic lesions mature. They are not the plaque itself but a marker of it. A patient with a high CAC score has likely had years of subclinical inflammation and lipid deposition even if every standard blood panel looks normal. That is the diagnostic power of the test: it reveals what circulating biomarkers miss.

The Agatston Score vs. Volume Score vs. Percentile

The Agatston score is the most cited metric, but two additional outputs matter in longevity practice:

Volume score. Calculated without the density weighting, it is slightly more reproducible on repeat scans and useful for tracking progression over time.

Age-sex-race percentile. The MESA (Multi-Ethnic Study of Atherosclerosis) cohort provided percentile norms for men and women across four ethnic groups from age 45 to 84. A 52-year-old White man with a CAC of 120 may sit at the 75th percentile for his demographic, which carries different prognostic weight than the raw number alone. The MESA CAC percentile calculator is freely available and referenced directly in the 2019 ACC/AHA guideline. [1]

Why Calcium Differs From Soft Plaque

Calcified plaque is generally more stable than lipid-rich soft plaque. A zero CAC score does not guarantee zero atherosclerosis; a patient with entirely non-calcified plaque could still have vulnerable lesions. For this reason, a CAC of zero should prompt lifestyle maintenance, not license for dietary recklessness. That nuance appears consistently in both the MESA literature and the 2019 ACC/AHA Primary Prevention Guideline. [2]

Target Range in Longevity Medicine: What Score Should You Aim For?

The longevity-medicine target is CAC = 0. That is not a marketing position. The MESA cohort (N = 6,814 initially asymptomatic adults followed for a median of 10.2 years) showed that participants with a CAC of zero had an annualized cardiovascular event rate of approximately 0.1%, compared with 1.2% per year in those with scores above 100. [3]

Reaching adulthood with a persistent CAC of zero into your 50s and 60s is a strong indicator of what longevity researchers sometimes call "favorable cardiovascular aging." The Framingham Heart Study offspring data showed that individuals maintaining CAC = 0 into the seventh decade of life had markedly lower lifetime cardiovascular risk than peers with equivalent LDL cholesterol levels but detectable calcium. [4]

The "CAC Zero Power" Concept

The term "CAC zero power" was popularized in part by analyses from the MESA and Dallas Heart Study cohorts showing that a zero score reclassifies intermediate-risk patients toward low risk with enough confidence to defer statin therapy safely. In the MESA primary prevention data, the negative predictive value of CAC = 0 for major adverse cardiovascular events over 10 years exceeded 99% in patients aged 45 to 75. [3]

This is the statistical basis for the 2019 ACC/AHA guideline statement that CAC = 0 "may be used to withhold statin therapy" in intermediate-risk patients who prefer to delay medication, particularly those aged below 66 without diabetes or smoking history. [2]

Scores Above Zero: Graduated Risk

Once calcium is detected, risk scales roughly logarithmically with score:

| CAC Range | Approximate 10-Year ASCVD Event Rate (MESA Data) | Guideline Recommendation | |-----------|--------------------------------------------------|--------------------------| | 0 | ~1% | May defer statins in intermediate-risk patients | | 1 to 99 | ~3 to 7% | Statin therapy favored; lifestyle intensification | | 100 to 399 | ~10 to 15% | Statin therapy indicated; high-intensity preferred | | 400 or above | ~20 to 25% | High-intensity statin indicated; consider cardiology referral |

These figures derive from MESA 10-year follow-up data published in JACC in 2012 and updated in subsequent analyses. [3]

How CAC Fits Into Longevity-Medicine Risk Assessment

Standard cardiovascular risk calculators like the Pooled Cohort Equations (PCE) use age, sex, blood pressure, cholesterol, smoking, and diabetes to estimate 10-year ASCVD risk. They are population-level tools with known individual-level imprecision. CAC scoring adds anatomic, patient-specific data that the PCE cannot model.

Reclassification Power

A study published in the New England Journal of Medicine using MESA data showed that adding CAC to a standard risk model improved the C-statistic for predicting coronary heart disease from 0.76 to 0.81. [5] More practically, it moved roughly one-third of intermediate-risk patients (PCE 7.5%, 20%) into either low-risk or high-risk categories, enabling more confident treatment decisions at both ends.

For longevity medicine, where the goal is preventing a first event rather than managing established disease, that reclassification is the clinical value of the scan. A 58-year-old man with borderline LDL and a PCE of 11% looks very different if his CAC is 0 versus 350.

When Guidelines Say to Order a CAC Scan

The 2019 ACC/AHA Primary Prevention Guideline (Arnett et al.) states: "In patients in whom a risk-based treatment decision is uncertain, CAC scoring is reasonable to guide the clinician and patient's decision whether to initiate statin therapy." [2] The guideline lists CAC as a Class IIa recommendation for this indication.

The Endocrine Society's clinical practice framework for cardiovascular risk in metabolic disease similarly endorses CAC as a useful tiebreaker when patients and clinicians disagree about the benefit-to-risk ratio of long-term statin use. [6]

The Specific Intermediate-Risk Window

CAC scanning provides the most decision-relevant data when:

• PCE 10-year risk falls between 7.5% and 20%
• LDL is between 70 and 189 mg/dL
• Patient preference or statin side-effect history creates equipoise
• Age is 40 to 75 years

Outside these boundaries, the scan rarely changes management. A patient with LDL of 210 mg/dL and a prior MI does not need a CAC scan to justify a high-intensity statin. A 35-year-old with no risk factors and PCE <5% gains little actionable information from the result.

CAC Score Progression: Why Longevity Medicine Tracks Change Over Time

A single CAC score is a snapshot. Serial scanning over years adds prognostic value beyond what either the baseline score or traditional risk factors provide alone.

What Annual Progression Rate Means

CAC progression is typically defined as an increase of more than 15% per year (some authors use absolute increases above 15 Agatston units annually). Data from the MESA cohort showed that rapid progressors, defined as an annualized increase above the 75th percentile for baseline score, had roughly double the cardiovascular event rate compared to slow progressors with the same baseline CAC. [7]

In longevity practice, this means a patient with CAC = 20 at age 52 and CAC = 95 at age 57 (a 375% increase over five years, or an annualized rate far above any threshold for "slow progression") warrants immediate treatment escalation even though neither individual value crosses 100. The trajectory matters.

How Statin Therapy Affects CAC Scores

Statins reliably slow CAC progression and in some analyses appear to cause moderate increases in CAC density (calcification of previously soft plaque), which may paradoxically stabilize lesions. The SATURN trial comparing rosuvastatin 40 mg to atorvastatin 80 mg found that both agents significantly slowed progression of total atheroma volume on IVUS, with rosuvastatin showing marginally greater regression. [8]

This creates an apparent paradox: statin-treated patients sometimes show higher CAC scores on follow-up scans, not because their disease is worsening but because soft plaque is mineralizing. Longevity clinicians should counsel patients on this before ordering a repeat scan after statin initiation to prevent unnecessary alarm.

Aspirin Decisions and CAC: The ASPREE and MESA Data

Aspirin for primary prevention has become one of the most contested areas in cardiovascular medicine following the publication of ASPREE, ARRIVE, and ASCEND trials showing that aspirin's bleeding risk outweighs its benefit in average-risk older adults. CAC scoring offers a biologically rational way to identify the subset who may still benefit.

The MESA Aspirin Analysis

A sub-analysis of MESA data published in JACC in 2017 found that among patients with CAC above 100, aspirin use was associated with a 36% relative risk reduction in coronary heart disease events (HR 0.64, 95% CI 0.42 to 0.99). Among patients with CAC = 0, no significant benefit was observed. [9]

These data do not constitute a randomized trial of aspirin stratified by CAC, so causality is not established. However, the signal is strong enough that the 2019 ACC/AHA guideline identifies high CAC scores (particularly above 100) as a potential "risk-enhancing factor" that might shift the benefit-risk calculus toward aspirin in younger patients (ages 40 to 59) at elevated baseline ASCVD risk.

What Longevity Clinicians Do With This in Practice

Most longevity medicine practitioners use the following tiered decision framework for aspirin:

• CAC = 0, age <60: Aspirin generally not recommended; focus on lifestyle.
• CAC 1 to 99, age <60: Shared decision-making; aspirin may be considered if additional risk factors are present (strong family history, metabolic syndrome, CRP above 2.0 mg/L).
• CAC 100 or above, age 40 to 59, no bleeding risk factors: Aspirin 81 mg daily is a reasonable option when discussed with the patient.
• CAC any value, age 60 or above: Aspirin for primary prevention is generally not recommended per 2022 USPSTF guidance regardless of CAC score. [10]

This framework is not a formal guideline consensus statement. It reflects the synthesis of MESA sub-analyses, ACC/AHA guidance, and USPSTF recommendations as applied in longevity medicine practice.

Special Populations: What Zero Means Differently by Age

A CAC of zero means something quite different at age 45 than at age 72.

Younger Patients (Ages 40 to 55)

At age 45, approximately 60 to 65% of asymptomatic adults in the MESA cohort had CAC = 0. A zero score here is expected, not exceptional. The longevity-relevant question is whether the score stays zero through the next decade. Annual lifestyle optimization (LDL below 70 mg/dL, blood pressure below 120/80 mmHg, non-smoking, HbA1c below 5.7%) is the intervention.

Middle-Aged Patients (Ages 56 to 65)

By age 60, roughly 45% of men and 65% of women in MESA still had CAC = 0. A zero score in a 62-year-old man is now genuinely favorable, sitting well above average. It indicates either genetic resistance to calcification or sustained cardiovascular health behaviors. Repeat scanning at 5-year intervals is reasonable. [3]

Older Patients (Ages 66 to 75)

Above age 65, a CAC of zero becomes progressively more rare in men (below 30% prevalence). When it occurs, it still confers protective prognostic information. However, a zero score in a 72-year-old should not override clinical judgment if multiple high-risk features are present, since non-calcified plaque burden may still be significant.

Preparing for a CAC Scan and Interpreting Your Report

The scan requires no contrast agent, no fasting, and no special preparation. Total scan time is under 10 minutes. Radiation dose is approximately 1 mSv, roughly equivalent to the background radiation from a round-trip flight from New York to Los Angeles. [11]

Reading the Report

Your report will include:

1. Total Agatston score. The primary number.
2. Per-vessel scores. Left main, LAD, LCX, and RCA reported separately. LAD involvement is particularly prognostically significant.
3. Volume score. Useful for serial comparison.
4. Age-sex percentile. Derived from MESA norms. This is often the most useful single number for clinical communication.

A score reported as "0" with "no calcified plaque identified" is a true negative result by CT. It does not rule out non-calcified soft plaque but is strongly reassuring.

When to Repeat Scanning

The 2019 ACC/AHA guideline does not mandate a specific repeat interval. Observational data suggest:

• CAC = 0: Repeat at 5 years if risk factors are stable. Some longevity clinicians extend to 7 years in low-risk patients with optimal lipids and blood pressure.
• CAC 1 to 99: Repeat at 3 to 5 years to assess progression velocity.
• CAC 100 or above: The scan has done its job; treatment is indicated. Repeat scanning provides less additional decision value unless assessing progression on therapy.

LDL, Inflammation, and CAC: How They Work Together

CAC is one node in a network of cardiovascular biomarkers. In longevity medicine, it is typically interpreted alongside:

LDL cholesterol (and ideally LDL particle number or ApoB). High LDL in the presence of zero CAC still warrants aggressive lifestyle management, particularly in younger patients where the absence of calcium may reflect a short exposure duration rather than resistance to atherogenesis. A 44-year-old with LDL of 185 mg/dL and CAC = 0 is not reassured of long-term safety; they have simply not yet accumulated enough plaque years to calcify.

High-sensitivity CRP (hsCRP). The JUPITER trial (N = 17,802) showed that patients with LDL below 130 mg/dL but hsCRP above 2.0 mg/L benefited from rosuvastatin 20 mg with a 54% reduction in cardiovascular events (HR 0.46, P<0.00001). [12] Elevated hsCRP alongside even a low CAC score shifts the risk calculus toward earlier statin initiation.

Lipoprotein(a) (Lp(a)). Lp(a) drives calcific aortic valve disease and coronary atherosclerosis through mechanisms partly independent of LDL. Patients with Lp(a) above 50 mg/dL and a rising CAC score represent a high-priority longevity intervention target, particularly as RNA-targeted Lp(a)-lowering therapies move through late-stage trials.

What High-Risk CAC Scores Mean for Treatment Intensity

When CAC is 100 or above, the 2019 ACC/AHA guideline supports initiating high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) to achieve at least a 50% reduction in LDL cholesterol. [2] Several practical points follow from this:

Statin Selection for CAC-Positive Patients

Atorvastatin 40 mg typically produces a 43 to 50% LDL reduction. Rosuvastatin 20 mg produces a similar range. In patients requiring greater reductions, adding ezetimibe 10 mg adds another 15 to 20% reduction at low side-effect cost. For patients with CAC above 400 and LDL above 130 mg/dL, a PCSK9 inhibitor (evolocumab or alirocumab) may be warranted if statin plus ezetimibe does not achieve the target LDL below 70 mg/dL.

Blood Pressure Targets When CAC Is Elevated

The ACC/AHA 2017 Hypertension Guideline (Whelton et al.) sets a target of below 130/80 mmHg for most adults with elevated cardiovascular risk. [13] In longevity medicine, patients with CAC above 100 are generally managed to below 120/80 mmHg systolic, consistent with the SPRINT trial finding that intensive blood pressure control (mean achieved SBP of 121 mmHg) reduced major cardiovascular events by 25% compared with standard targets in non-diabetic adults at elevated CV risk. [14]

Lifestyle Interventions That Demonstrably Slow CAC Progression

Four interventions have the best evidence for slowing CAC progression:

1. Statin therapy (described above).
2. Aggressive LDL lowering below 70 mg/dL, even in patients not meeting traditional statin-indication thresholds.
3. Blood pressure control below 130/80 mmHg.
4. Smoking cessation. The relative risk of CAC progression in active smokers vs. Never-smokers in MESA was approximately 2.0 after adjustment for baseline score and other risk factors. [7]

No randomized trial has shown that diet or exercise alone reverses existing CAC. Exercise may slow progression, and the Mediterranean diet is associated with lower incident CAC in observational data, but the effect sizes are smaller than pharmacotherapy.